Oramed Story

ORMP -- USA Stock

USD 5.53 0.95 20.74%

Macroaxis Story

The next earnings report is expected on the 14th of January 2021. The stock is currently experiences an active upward rally. As many millenniums are getting excited about healthcare space, it is only fair to recap the feasibility of shorting Oramed Pharmaceuticals. We will evaluate why we are still optimistic in anticipation of a recovery.

Published over a month ago

View all stories for Oramed Pharmaceuticals | View All Stories

Do analysts believe Oramed Pharmaceuticals (NASDAQ:ORMP) will continue to roll up?

Oramed Pharmaceuticals is UNDERVALUED at 6.46 per share with modest projections ahead. We provide trade recommendations to complement the recent expert consensus on Oramed Pharmaceuticals. Our dynamic recommendation engine exercises a multidimensional algorithm to analyze the firm's potential to grow using all technical and fundamental data available at the time.

What is the right price you would pay to acquire a share of Oramed Pharmaceuticals? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our stock advisor page.

What is happening with Oramed Pharmaceuticals this year

Annual and quarterly reports issued by Oramed Pharmaceuticals are formal financial statements that are published yearly and quarterly and sent to Oramed stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the Securities and Exchange Commission (SEC) for businesses owned by the public since 1934. Companies such as Oramed Pharmaceuticals often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.

How Oramed utilizes its cash?

To perform a cash flow analysis of Oramed Pharmaceuticals, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Oramed Pharmaceuticals is receiving and how much cash it distributes out in a given period. The Oramed Pharmaceuticals cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Is Oramed a risky opportunity?

Let's check the volatility. Oramed is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Oramed (NASDAQ:ORMP) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. obtaining a share of an Oramed Pharmaceuticals stock makes you a part-owner of that company.

Oramed Pharmaceuticals Current Consensus

Here is the recent trade recommendation based on an ongoing consensus estimate among financial analysis covering Oramed Pharmaceuticals. The Oramed consensus assessment is calculated by taking the average estimates from all of the analysts covering Oramed Pharmaceuticals

Strong Buy

Strong Buy	3	100.0
Buy	0	0.0
Hold	0	0.0
Sell	0	0.0
Strong Sell	0	0.0

Our perspective of the recent Oramed Pharmaceuticals roll up

Kurtosis is down to 17.04. It may hint at a possible volatility decline. As of the 28th of November, Oramed Pharmaceuticals holds the Coefficient Of Variation of 1176.48, risk adjusted performance of 0.115, and Semi Deviation of 3.8. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Oramed Pharmaceuticals, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to analyze and collect data for nineteen technical drivers for Oramed Pharmaceuticals, which can be compared to its competitors. Please check Oramed Pharmaceuticals standard deviation, as well as the relationship between the maximum drawdown and expected short fall to decide if Oramed Pharmaceuticals is priced some-what accurately, providing market reflects its current price of 4.45 per share. Given that Oramed Pharmaceuticals has jensen alpha of 0.4741, we recommend you to check out Oramed Pharmaceuticals's recent market performance to make sure the company can sustain itself at a future point.

Our Takeaway on Oramed Pharmaceuticals Investment

Although other entities under the biotechnology industry are still a bit expensive, Oramed Pharmaceuticals may offer a potential longer-term growth to insiders. While some insiders may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Oramed Pharmaceuticals.

About Contributor

Gabriel Shpitalnik is a Member of Macroaxs Editorial Board. Gabriel is a young entrepreneur and writes predominantly on the business, technology, and finance sector. He likes to analyze different equity instruments across a wide range of industries focusing primarily on consumer products and evolving technologies. View Profile

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Oramed Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2021 Macroaxis LLC